alliReport

Free! Join

Discussions
Your INDEPENDENT source of news about the new diet drug alli (low-dose Xenical)
 
alli News from January 2006 -- News About Low-Dose Xenical
 

Article Urges FDA to Limit Acomplia to "Those Who Need the Drug to Survive"

 

A Virginia Tech student newspaper has gotten quite a bit of attention in the past two days with an article on Acomplia suggesting that while a pill that combats obesity and potentially decreases the risk of heart complications sounds like a great idea, it "could end up creating more problems than it solves."

In the article, the Collegiate Times, which provides a news feed to the giant search engine Google, calls on the U.S. Food and Drug Administration -- which is currently considering approval of Acomplia -- to regulate the drug "so as to ensure that only those who need the drug to survive receive it.

Here are highlights from the Collegiate Times article:

"No matter how effective Acomplia (or any other weight-loss drug after it, for that matter) turns out to be, no pill will ever be an adequate substitute for proper dieting and exercise. People need to realize that losing weight and living healthy is a lifestyle change that brings along with it a completely different mentality, not just a magic pill they can take to achieve instant results.

"Therein lies the key problem with any weight-loss medication — too many individuals want instantaneous results and are unwilling to do more than pop a few pills each day to achieve them. Then what happens if the drug doesn’t work? Some will take more and more to try to increase the effect of each dosage — and that leads to addiction.

"Further, eating is a great source of pleasure for many who are overweight or obese. If they’re on a pill that suppresses their appetites, depression could follow if these individuals fail to replace food consumption with another healthy habit.

"Despite the potential negative effects it could cause, Acomplia could be used extremely effective to treat people who are clinically obese due to genetics, who have diseases that cause them to be overweight, or who have gained weight due to complications from a medical condition such as type 2 diabetes.

"And this is exactly how the drug should be sold — as medicine for those who truly need it, not simply as another option for those who just want to lose weight. Because if a medicine that makes its users lose weight rapidly fell into the wrong hands, death could result from simply not knowing when to quit — as is the case with anorexia sufferers.

"The best solution is for the FDA to regulate Acomplia so as to ensure that only those who need the drug to survive receive it. Without regulation, this miracle pill may not turn out to be so miraculous after all."

 
 
 
 
 

 

Other Diet Resources
Privacy Policy | Terms and Disclaimers | About the alli Report
Click to VerifyWe subscribe to the HONcode principles of the HON Foundation.
This is an independent news site reporting on alli, a half-strength version of the diet drug Xenical (orlistat), which GlaxoSmithKlein hopes to market under the trademarked name alli. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided is for informational purposes only. Always consult a doctor or medical professional with questions regarding a medical condition.

Last Updated: 02/09/2007 Copyright 2004-2006 Medical Week News, Inc. All Rights Reserved